Switching strategies to improve lipid profile and morphologic changes

AIDS Reviews

Volumn 8, Issue 4, 2006, Pages 191-203

  Barragan, Patricia ^a   Fisac, Cesar ^a   Podzamczer, Daniel ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Cardiovascular risk; Lipid abnormalities; Lipoatrophy; Simplification therapy; Switching strategies

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; EFAVIRENZ; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; THYMIDINE DERIVATIVE; ZIDOVUDINE;

BODY FAT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSLIPIDEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLACTATEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPOATROPHY; LIPODYSTROPHY; METABOLIC DISORDER; OBESITY; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS RESISTANCE;

ANTI-HIV AGENTS; CLINICAL TRIALS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LIPID METABOLISM;

EID: 33846442010     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced HIV infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
2. Mellors J, Munoz A, Giorgi J, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54.
3. Carr A, Cooper D. Adverse effects of antiretroviral therapy. Lancet 2000;356:1423-30.
4. Chen D, Misra A, Garg A. Lipodystrophy in HIV-infected patients. J Clin Endocrinol Metab 2002;87:4845-56.
5. Dube M, Fenton M. Lipid abnormalities. Clin Infect Dis 2003;36(Suppl 2):S79-83.
6. Gelato M. Insulin and carbohydrate dysregulation. Clin Infect Dis 2003;36(Suppl 2):S91-5.
7. Holmberg S, Moorman A, Greenberg A, Friis-Moller N. The DAD Study group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003.
8. Sabin C, Friis-Moller N, Reiss P, et al. Risk factors for new onset diabetes mellitus in HIV patients. 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil 2005. [abstract TuPe2.2B28].
9. Friis-Moller N, Reiss P, El-Sadr W, et al. Exposure to PI and NNRTI and risk of myocardial infarction: Results from the DAD Study. 13th CROI, Denver 2006. [abstract 144].
10. Holmberg S, Moorman A, Williamson J, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002;360:1747-8.
11. Lee G, Seneviratne T, Norr M, et al. The metabolic effects of lopinavir/ ritonavir in HIV-negative men. AIDS 2004;18:641-9.
12. Noor M, Lo J, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001;15:F11-18.
13. Goldsmith D, Perry C. Atazanavir. Drugs 2003;63:1679-93.
14. Van der Valk M, Gisolf E, Reiss P, et al. Increased risk of lipodystrophy when nucleoside analog reverse transcriptase inhibitors are included with PI in the treatment of HIV-1 infection. AIDS 2001;15:847-55.
15. Mallal S, John M, Moore C, James I, et al. Contribution of nucleoside analog reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000;14:1309-16.
16. Saves M, Chene G, Suissa S. Lipodystrophy and nucleoside analog therapy in HIV-infected patients: important question, few valid answers. JAIDS 2000;25:96-7.
17. Bogner J, Vielhauer V, Beckmann R, et al. Stavudine versus zidovudine and the development of lipodystrophy. JAIDS 2001;27:237-44.
18. St Marc T, Touraine J. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy. AIDS 1999;13:2188-9.
19. Saint Marc T, Partisans M, Poizor-Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000;14:37-49.
20. Montaner J, Reiss P, Cooper D, et al. A randomized double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, the Netherlands, Canada and Australia study. JAMA 1998;279:930-7.
21. Podzamczer D, Ferrer E, Consiglio E, et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (The Combine Study). Antivir Ther 2002;7:81-90.
22. Staszewski S, Morales-Ramirez J, Tashima K, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999;341:1865-73.
23. Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine vs. indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA 2001;285:1155-63.
24. Carr A, Thorisdottir A, Samaras K, et al. Reversibility of PI lipodystrophy syndrome on stopping PI and switching to nelfinavir. 6th CROI, Chicago 1999 [abstract 641].
25. Martinez E, Lozano L, Conget I, et al. Reversion of lipodystrophy after switching HIV-1 PI to nevirapine. AIDS 1999;13:805-10.
26. Tebas P, Yarashesky K, Powderly W, et al. A prospective open-label pilot trial of maintenance nevirapine-containing regimens in patients with undetectable viral loads on PI regimens for at least 6 months. 7th CROI, San Francisco 2000 [abstract 45].
27. Dieleman J, Sturkenboom M, Ferdinand W, et al. Low risk of treatment failure after substitution of nevirapine for PI among HIV-infected patients with virus suppression. The Journal of Infectious Diseases 2002;185:1261-8.
28. Barreiro P, Soriano V, Blanco F, Casimiro C, de la Cruz J, González-Lahoz J. Risk and benefits of replacing PI by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000;14:807-12.
29. Ruiz L, Negredo E, Domingo P, et al. Clinical, virologic and immunologic benefit of switching the PI by nevirapine in HAART-experienced patients suffering lipodystrophy: 48-weeks follow-up. JAIDS 2001;27:229-36.
30. Moyle G, Baldwin C, Mandalia S, Comitis S, Burn P, Gazzard B. Changes in metabolic parameters and body shape after replacement of PI with efavirenz in virologically controlled HIV-1-positive persons: single-arm observational cohort. J Acquir Immune Defic Syndr 2001;28:399-401.
31. Negredo E, Cruz L, Paredes R, et al. Virologic, immunologic and clinical impact of switching from PI to nevirapine or to efavirenz in patients with HIV infection and long-lasting viral suppression. Clin Infect Dis 2002;34:504-10.
32. Viciana P, Alarcon A, Martin D, et al. Partial improvement of lipodystrophy after switching from HIV-1 PI to efavirenz. 7th CROI. San Francisco 2000 [abstract 48].
33. Estrada V, De Villar N, Larrad M, Lopez A, Fernandez C, Serrano-Ríos M. Long-term metabolic consequences of switching from PI to efavirenz in therapy for HIV-infected patients with lipoatrophy. Clin Infect Dis 2002;35:69-76.
34. Rozenbaum W, Adda N, Nguyen T, et al. Prospective follow-up substitution of PI for efavirenz in patients with HIV-related lipodystrophy syndrome. 1st International Workshop on Adverse Drugs Reactions and Lipodystrophy in HIV. San Diego, 1999.
35. Bonnet E, Lepec R, Bluteau M, et al. Evolution of lipodystrophy syndrome and lipid profile in HIV patients after switching from PI to efavirenz. 7th CROI. San Francisco 2000 [abstract 49].
36. Martinez E, García-Viejo M, Blanco J, et al. Impact of switching from HIV-1 PI to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis 2000;31:1266-74.
37. Hirschel B, Flepp M, Bucher H, et al. Switching from PI to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort. AIDS 2002;16:381-5.
38. Young J, Weber R, Rickenbach M, et al. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV Cohort Study. Antiviral Therapy 2005;10:585-91.
39. Young J, Rickenbach M, Weber R, et al. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV Cohort study. Antiviral Therapy 2005;10:73-81.
40. Harris M, Larsen G, Montaner J, et al. Replacing PI for efavirenz for management of PI toxicity. 1st International Workshop on Adverse Drugs Reactions and Lipodystrophy in HIV. San Diego, 1999.
41. Martinez E, Romeu J, García-Viejo M, et al. An open randomized study on the replacement of HIV-1 PI by efavirenz in chronically suppressed HIV-1 infected patients with lipodystrophy. 8th CROI, Chicago 2001 [abstract 668].
42. Becker S, Rachlis A, Gill J, et al. Successful substitution of PI with efavirenz in patients with undetectable viral loads. A prospective, randomized, multicenter, open-label study (DMP 049). 8th CROI, Chicago 2001 [abstract 20].
43. Katlama C. Successful substitution of PI with Sustiva (efavirenz) in patients with undetectable plasma HIV-1 RNA levels: results of a prospective, randomized, multicenter, open-label study (DMP 266-027). XIII IAS, 2000 [abstract LbPeB7044].
44. Clumeck N, Goebel F, Rozenbaum W, et a]. Simplification with abacavir-based triple nucleoside therapy versus continued PI-based HAART in HIV-1 infected patients with undetectable plasma HIV-1 RNA. AIDS 2001;15:1517-26.
45. Katlama C, Fenske S, Gazzard B, et al. TRIZAL study: switching from successful HAART to TRIZIVIR (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med 2003;4:79-86.
46. Opravil M, Hirschel B, Lazzarin A, et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine and zidovudine in HIV infection. J Infect Dis 2002;185:1251-60.
47. Pulvirenti J, Goodwin D, Slater L, et al. Simplification of PI-containing HAART regimens with abacavir maintains viral suppression and favorable adherence in HIV-1 infected adults (COLA 30305). Program and abstract of the 39th Annual Meeting of the Infectious Diseases Society of America, 2001, San Francisco [abstract 689].
48. Keiser P, Sension M, DeJesus E, et al. Substituting abacavir for hyperlipidemia-associated PI in HAART regimens improves fasting lipid profiles, maintains virologic suppression and simplifies treatment. BMC Infect Dis 2005;5:2.
49. Moebius U, Lubach-Ruitman M, Castro-Frenzel B, et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. JAIDS 2005; 39:174-80.
50. Gatell J, Branco T, Sasset L, et al. Efficacy and safety of atazanavir-based HAART in virologically suppressed subjects switched from lopinavir/ritonavir treatment (Subset Analysis of the Swan Study) AIDS 2006 XVI International AIDS Conference, Toronto, Canada.
51. Wood R, Phanuphak P, Cahn P, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Synd 2004;36:684-92.
52. Sension M, Grinsztejn B, Molina J. Improvement in lipid profiles after 12 weeks of switching to atazanavir from boosted or unboosted PI in patients with no previous PI virologic failure and hyperlipidemia at baseline. 12th CROI, Boston, USA, 2005.
53. Haerter G, Burkhard J, Mueller M, et al. Regression of lipodystrophy in HIV-infected patients under therapy with the new PI atazanavir. AIDS 2004;18:952-4.
54. Martínez E, Azuaje CJ, Antela A, et al. Effects of switching to ritonavir-boosted atazanavir on HIV-infected patients receiving antiretroviral therapy with hyperlipidemia. 12th CROI, Boston, USA 2005.
55. Casado J, Arrizabalaga J, Antela A, et al. Long-term efficacy and tolerance of switching the PI for NNRTI: A 52 week, multicenter, prospective study. 8th CROI, Chicago 2001 [abstract 673].
56. Van de Valk M, Kastelein J, Murphy R, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001;15:2407-14.
57. Fisac C, Virgili N, Ferrer E, et al. A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in anti-retroviral-naive HIV-infected patients: a randomized controlled study. J Clin Endocrinol Metab 2003;88:5186-92.
58. Martinez E, Arnaiz J, Podzamczer D, et al. Substitution of nevirapine, efavirenz, or abacavir for PI in patients with HIV infection. N Engl J Med 2003;349:1036-46.
59. Fisac C, Fumero E, Crespo M, et al. Metabolic benefits 24 months after replacing a PI with abacavir, efavirenz or nevirapine. AIDS 2005;19:917-25.
60. Maggiolo F, Ripamonti D, Ravasio L, et al. Outcome of two simplification strategies for the treatment of HIV-1 infection. Clin Infect Dis 2003;37:41-9.
61. McComsey G, Ward D, Hessenthaler M, et al. Improvement in lipoatrophy associated with HAART in HIV-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 2004;38:263-70.
62. McComsey G, Paulsen D, Lonergan J, et al. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005;19:15-23.
63. Cherry C, Lal L, Thompson K, et al. Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from stavudine to abacavir or zidovudine. J Acquir immune Defic Syndr 2005;38:263-7.
64. Garcia-Benayas T, Blanco F, De la Cruz J, et al. Replacing stavudine by abacavir reduces lactate levels and may improve lipoatrophy. AIDS 2003;17:921-4.
65. Carr A, Workman C, Smith D, et al. Abacavir substitution for nucleosides analogs in patients with HIH lipoatrophy. JAMA 2002; 288:207-15.
66. Martin A, Smith D, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients two years after switching from thymidine analog to abacavir: The Mitox Extension Study. AIDS 2004;18:1029-36.
67. John M, McKinnon E, James I, et al. Randomized, controlled, 48-week study of switching stavudine and/or PI to Combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir immune Defic Syndr 2003;33:29-33.
68. Moyle G, Baldwin C, Langroudi B, et al. A 48-week, randomized, open-label comparison of three abacavir-substitution approaches in the management of dyslipidemia and peripheral atrophy. J Acquir immune Defic Syndr 2003;33:22-8.
69. Ribera E, Paradiñeiro J, Sauleda S, et al. Improvements in subcutaneous fat, lipid profile and parameters of mitochondria toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study). Program and abstracts of the 12th CROI, 2005, Boston, USA [abstract 860].
70. Gallant J, Staszewski S, Pozniak A, et al. The 903 Study Group. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients. JAMA 2004;292:191-201.
71. Madruga J, Cassetti I, Suleiman J, et al. Improvement in lipoatrophy and lipid abnormalities following switch from stavudine to tenofovir in combination with lamivudine and efavirenz in HIV-infected patients: a 48 week follow-up from study 903e. Program and abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment, 2005, Rio de Janeiro, Brazil [abstract TuPe2.2B12].
72. Domingo P, Labarga P, Palacios R, et al. Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results. AIDS 2004;18:1475-7.
73. Llibre J, Domingo P, Perez M, et al. Recover Study Group. Improvements in dyslipidemia at 48-weeks following substitution of stavudine with tenofovir DF. 7th International Workshop on Adverse Drug Reactions & Lipodystrophy in HIV. Dublin, Ireland, 2005.
74. Llibre J, Domingo P, Palacios R, et al. The LIPO-REC Study Group. Sustained improvement of dyslipidemia in HAART-treated patients replacing stavudine with tenofovir. AIDS 2006;20:1407-14.
75. Moyle G, Sabin C, Cartledge J, et al. A 48-week, randomized, open- label comparative study of tenofovir DF vs. abacavir as substitutes for a thymidine analog in persons with lipoatrophy and sustained virologic suppression on HAART. Program and abstracts of the 12th CROI, Boston, USA [abstract 44LB].
76. Milinkovic A, Lopez S, Vidal S, et al. A randomized open study comparing the effect of reducing stavudine dose vs. switching to tenofovir on mitochondrial function, metabolic parameters, and subcutaneous fat in HIV-infected patients receiving antiretroviral therapy containing stavudine. 12th CROI, 2005 [abstract 857].
77. Tebas P, Zhang J, Yarasheski K, et al. Switch to a PI-containing/ NRTI-sparing regimen increases appendicular fat and serum lipid levels without affecting glucose metabolism or bone mineral density. The results of a prospective randomized trial, ACTG5125s. 12th CROI. Boston 2005 [abstract 40].
78. Murphy R, Zhang J, Hafner R, et al. Switching to a thymidine analog-sparing or a nucleoside-sparing regimen improves lipoatrophy: 24-week results of a prospective randomized clinical trial, ACTG5110. 12th CROI. Boston 2005 [abstract 45LB].
79. Negredo E, Molto J, Burger D, et al. Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study). J Acquir Immune Defic Syndr 2005;38:47-52.